InvestSMART

Optiscan Imaging Limited (ASX: OIL) - Announcements

Current share price for OIL : $0.160 0.005 (3.23%)+

ASX company news and announcements for Optiscan Imaging Limited (OIL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Optiscan Imaging Limited (OIL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Optiscan Imaging Limited (OIL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Optiscan Imaging Limited (OIL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$167 Optiscan Lodges U.S. FDA 510(k) Submission for InVue 5 Oct 2026 9:13AM $0.165 $0.160 fallen by 3.03%
$167 Optiscan Lodges U.S. FDA 510(k) Submission for InForm 1 Oct 2026 2:42PM $0.135 $0.160 risen by 18.52%
$167 Change of Director's Interest Notice 16 Sep 2026 9:04AM $0.145 $0.160 risen by 10.34%
$167 Notification of cessation of securities - OIL 16 Sep 2026 8:26AM $0.145 $0.160 risen by 10.34%
$167 Application for quotation of securities - OIL 16 Sep 2026 8:25AM $0.145 $0.160 risen by 10.34%
$167 Significant Milestone Reached in ACL Digital Pathology Study 10 Sep 2026 8:48AM $0.150 $0.160 risen by 6.67%
$167 Change of Director's Interest Notice 10 Sep 2026 8:43AM $0.150 $0.160 risen by 6.67%
$167 Application for quotation of securities - OIL 10 Sep 2026 8:40AM $0.150 $0.160 risen by 6.67%
$167 Application for quotation of securities - OIL 9 Sep 2026 8:26AM $0.150 $0.160 risen by 6.67%
$167 Change of Director's Interest Notice 9 Sep 2026 8:24AM $0.150 $0.160 risen by 6.67%
$167 Change of Director's Interest Notice 9 Sep 2026 8:24AM $0.150 $0.160 risen by 6.67%
$167 Optiscan Initiates Head and Neck Cancer Study in the US 1 Sep 2026 8:21AM $0.155 $0.160 risen by 3.23%
$167 Appendix 4G & Corporate Governance Statement 25 Aug 2026 8:47AM $0.175 $0.160 fallen by 8.57%
$167 2026 Annual Report 25 Aug 2026 8:47AM $0.175 $0.160 fallen by 8.57%
$167 Preliminary Final Report 25 Aug 2026 8:45AM $0.175 $0.160 fallen by 8.57%
$167 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2026 9:18AM $0.150 $0.160 risen by 6.67%
$167 Optiscan Signs New Research Agreement for Breast Study 22 Jul 2026 8:25AM $0.140 $0.160 risen by 14.29%
$167 Head and Neck Study Progressing Ahead of Schedule 21 Jul 2026 8:33AM $0.155 $0.160 risen by 3.23%
$167 Optiscan Launches InSpecta Device for Veterinary Medicine 7 Jul 2026 8:20AM $0.135 $0.160 risen by 18.52%
$167 Halfway Mark Reached in Optiscan Breast Cancer Study 4 Jun 2026 8:39AM $0.130 $0.160 risen by 23.08%
$167 Second Anniversary of Optiscan and Mayo Clinic Agreement 1 Jun 2026 11:32AM $0.125 $0.160 risen by 28%
$167 Change of Director's Interest Notice 25 May 2026 4:11PM $0.110 $0.160 risen by 45.45%
$167 Optiscan Receives $1.69m R&D Tax Refund 20 May 2026 8:44AM $0.108 $0.160 risen by 48.84%
$167 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2026 8:47AM $0.105 $0.160 risen by 52.38%
$167 Optiscan Submits InSpecta FDA Dossier 31 Mar 2026 9:30AM $0.105 $0.160 risen by 52.38%

1 - 25 of 633 results

Page 1 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.